1
|
Bedogni A, Bettini G, Bedogni G, Basso D, Gatti D, Valisena S, Brunello A, Sorio M, Berno T, Giannini S, Navaglia F, Plebani M, Nocini PF, Blandamura S, Saia G, Bertoldo F. Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study. J Craniomaxillofac Surg 2019; 47:1203-1208. [PMID: 30929994 DOI: 10.1016/j.jcms.2019.03.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Revised: 01/11/2019] [Accepted: 03/06/2019] [Indexed: 01/07/2023] Open
Abstract
PURPOSE A previous case-control histomorphometric study showed higher odds of osteomalacia in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ). Vitamin D deficiency causes osteomalacia and may therefore be involved in the pathogenesis of BRONJ. The present case-control study aimed at testing such hypothesis. MATERIALS AND METHODS BRONJ+ and BRONJ- patients treated with bisphosphonates were matched by sex (same) and age (within 5 years). Serum 25-hydroxy-vitamin D (25-OH-D), parathyroid hormone, bone alkaline phosphatase, total procollagen type 1 amino-terminal propeptide, carboxy-terminal collagen crosslinks, Dickkopf WNT signaling pathway inhibitor 1 and sclerostin were measured. RESULTS The main outcome was vitamin D deficiency defined as 25-OH-D < 50 nmol/l. A total of 51 BRONJ+ and 73 BRONJ- patients were studied. The frequency (95% CI) of vitamin D deficiency was 59% (45%-72%) in BRONJ+ and 62% (48%-75%) in BRONJ- patients. This amounts to a difference of -3% (-22%-16%, p = 0.77) for BRONJ+ patients. Serum 25-hydroxy-vitamin D and parathyroid hormone were similar in BRONJ+ and BRONJ- patients. Among the bone metabolism markers, only sclerostin differed between the two groups, being higher in BRONJ+ patients. CONCLUSION The present matched case-control study suggests that vitamin D deficiency is not a risk factor for BRONJ.
Collapse
Affiliation(s)
- Alberto Bedogni
- Unit of Maxillofacial Surgery, Department of Neuroscience-DNS, University of Padua, Padua, Italy.
| | - Giordana Bettini
- Unit of Maxillofacial Surgery, Department of Neuroscience-DNS, University of Padua, Padua, Italy
| | - Giorgio Bedogni
- Clinical Epidemiology Unit, Liver Research Center, Basovizza, Trieste, Italy
| | - Daniela Basso
- Unit of Laboratory Medicine, Department of Medicine-DIMED, University of Padua, Padua, Italy
| | - Davide Gatti
- Unit of Rheumatology, Department of Medicine, University of Verona, Verona, Italy
| | - Silvia Valisena
- Service of Traumatology, Orthopedics and Hand Surgery, Regional Hospital of Bellinzona, Switzerland
| | | | - Marco Sorio
- Unit of Hematology, Department of Medicine, University of Verona, Verona, Italy
| | - Tamara Berno
- Hematology and Clinical Immunology Branch, Department of Medicine-DIMED, University of Padua, Padua, Italy
| | - Sandro Giannini
- Unit of Internal Medicine, Department of Medicine-DIMED, University of Padua, Padua, Italy
| | - Filippo Navaglia
- Unit of Laboratory Medicine, Department of Medicine-DIMED, University of Padua, Padua, Italy
| | - Mario Plebani
- Unit of Laboratory Medicine, Department of Medicine-DIMED, University of Padua, Padua, Italy
| | - Pier Francesco Nocini
- Unit of Oral and Maxillofacial Surgery, Department of Surgery, University of Verona, Verona, Italy
| | | | - Giorgia Saia
- Unit of Maxillofacial Surgery, Department of Neuroscience-DNS, University of Padua, Padua, Italy
| | - Francesco Bertoldo
- Unit of Internal Medicine, Department of Medicine, University of Verona, Verona, Italy
| |
Collapse
|
2
|
Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B. Risks and Benefits of Bisphosphonate Therapies. J Cell Biochem 2016; 117:20-8. [PMID: 26096687 DOI: 10.1002/jcb.25266] [Citation(s) in RCA: 88] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 06/17/2015] [Indexed: 12/28/2022]
Abstract
Bisphosphonates are the mainstay of osteoporosis treatment but also play a fundamental role in treating other bone diseases such as Osteogenesis Imperfecta, Pagets' disease, and in the prevention of adverse skeletal effects in certain cancers such as prostate cancer or multiple myeloma. In the last decades, the refinement of bisphosphonates and an increase in the number of new bisphosphonates commercialized has altered the clinical management of these diseases. Despite differences between randomized controlled trials and observational studies, overall all bisphosphonates licensed have proven to reduce the risk of fracture through the inhibition of bone resorption. Other beneficial effects include pain reduction in bone metastasis and potentially a decrease in mortality. However, the chronic nature of most of these disorders implies long-term treatments, which can be associated with long-term adverse effects. Some of the adverse effects identified include an increased risk of atypical femur fractures, osteonecrosis of the jaw, gastrointestinal side effects, or atrial fibrillation. The harm/benefit thinking and the constant update regarding these medications are vital in the day-to-day decision-making in clinical practices. The aims of this review are to compile the basic characteristics of these drugs and outline the most important benefits and side effects and provide a clinical context as well as a research agenda to fill the gaps in our knowledge.
Collapse
Affiliation(s)
- Carlen Reyes
- GREMPAL Research Group, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain
| | - Mette Hitz
- Department of Endocrinology, Copenhagen University Hospital Hvidovre, Kettegaards Alle, Hvidovre, Denmark
| | - Daniel Prieto-Alhambra
- GREMPAL Research Group, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain.,URFOA-IMIM and RETICEF, Parc de Salut Mar and Instituto de Salud Carlos III, Barcelona, Spain.,Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, OX3 7LD, UK
| | - Bo Abrahamsen
- Odense Patient Data Explorative Network, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.,Department of Medicine, Holbaek Hospital, Holbaek, Denmark
| |
Collapse
|
3
|
Xiong L, Xia WF, Tang FL, Pan JX, Mei L, Xiong WC. Retromer in Osteoblasts Interacts With Protein Phosphatase 1 Regulator Subunit 14C, Terminates Parathyroid Hormone's Signaling, and Promotes Its Catabolic Response. EBioMedicine 2016; 9:45-60. [PMID: 27333042 PMCID: PMC4972523 DOI: 10.1016/j.ebiom.2016.05.028] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Revised: 05/11/2016] [Accepted: 05/24/2016] [Indexed: 12/02/2022] Open
Abstract
Parathyroid hormone (PTH) plays critical, but distinct, roles in bone remodeling, including bone formation (anabolic response) and resorption (catabolic response). Although its signaling and function have been extensively investigated, it just began to be understood how distinct functions are induced by PTH activating a common receptor, the PTH type 1 receptor (PTH1R), and how PTH1R signaling is terminated. Here, we provide evidence for vacuolar protein sorting 35 (VPS35), a major component of retromer, in regulating PTH1R trafficking, turning off PTH signaling, and promoting its catabolic function. VPS35 is expressed in osteoblast (OB)-lineage cells. VPS35-deficiency in OBs impaired PTH(1–34)-promoted PTH1R translocation to the trans-Golgi network, enhanced PTH(1–34)-driven signaling, and reduced PTH(1–34)'s catabolic response in culture and in mice. Further mechanical studies revealed that VPS35 interacts with not only PTH1R, but also protein phosphatase 1 regulatory subunit 14C (PPP1R14C), an inhibitory subunit of PP1 phosphatase. PPP1R14C also interacts with PTH1R, which is necessary for the increased endosomal PTH1R signaling and decreased PTH(1–34)'s catabolic response in VPS35-deficient OB-lineage cells. Taken together, these results suggest that VPS35 deregulates PTH1R-signaling likely by its interaction with PTH1R and PPP1R14C. This event is critical for the control of PTH(1–34)-signaling dynamics, which may underlie PTH-induced catabolic response and adequate bone remodeling. VPS35 terminates PTH(1-34)-induced cell surface and endosomal signalings Osteoblastic VPS35 promotes PTH(1-34)-driven catabolic response VPS35 interacts with PPP1R14C PPP1R14C also interacts with PTH1R and promotes PTH(1-34)-induced endosomal signaling PPP1R14C is necessary for the increased endosomal PTH1R signaling and decreased PTH(1-34)’s catabolic response in VPS35-deficient OB-lineage cells
Collapse
Affiliation(s)
- Lei Xiong
- Department of Neuroscience & Regenerative Medicine, Department of Neurology, Medical College of Georgia, Augusta, GA 30912, United States; Charlie Norwood VA Medical Center, Augusta, GA 30912, United States
| | - Wen-Fang Xia
- Department of Neuroscience & Regenerative Medicine, Department of Neurology, Medical College of Georgia, Augusta, GA 30912, United States; Charlie Norwood VA Medical Center, Augusta, GA 30912, United States; Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - Fu-Lei Tang
- Department of Neuroscience & Regenerative Medicine, Department of Neurology, Medical College of Georgia, Augusta, GA 30912, United States; Charlie Norwood VA Medical Center, Augusta, GA 30912, United States
| | - Jin-Xiu Pan
- Department of Neuroscience & Regenerative Medicine, Department of Neurology, Medical College of Georgia, Augusta, GA 30912, United States; Charlie Norwood VA Medical Center, Augusta, GA 30912, United States
| | - Lin Mei
- Department of Neuroscience & Regenerative Medicine, Department of Neurology, Medical College of Georgia, Augusta, GA 30912, United States; Charlie Norwood VA Medical Center, Augusta, GA 30912, United States
| | - Wen-Cheng Xiong
- Department of Neuroscience & Regenerative Medicine, Department of Neurology, Medical College of Georgia, Augusta, GA 30912, United States; Charlie Norwood VA Medical Center, Augusta, GA 30912, United States.
| |
Collapse
|
4
|
Griz L, Fontan D, Mesquita P, Lazaretti-Castro M, Borba VZC, Borges JLC, Fontenele T, Maia J, Bandeira F. Diagnosis and management of Paget's disease of bone. ACTA ACUST UNITED AC 2015; 58:587-99. [PMID: 25211441 DOI: 10.1590/0004-2730000002941] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2013] [Accepted: 03/18/2014] [Indexed: 01/25/2023]
Abstract
OBJECTIVE To conduct a literature review on the diagnosis and management of Paget's disease of bone. MATERIALS AND METHODS This scientific statement was generated by a request from the Brazilian Medical Association (AMB) to the Brazilian Society of Endocrinology and Metabolism (SBEM) as part of its Clinical Practice Guidelines program. Articles were identified by searching in PubMed and Cochrane databases as well as abstracts presented at the Endocrine Society, Brazilian Society for Endocrinology Annual Meetings and the American Society for Bone and Mineral Research Annual Meeting during the last 5 years. Grading quality of evidence and strength of recommendation were adapted from the first report of the Oxford Centre for Evidence-based Medicine. All grades of recommendation, including "D", are based on scientific evidence. The differences between A, B, C and D, are due exclusively to the methods employed in generating evidence. CONCLUSION We present a scientific statement on Paget's disease of bone providing the level of evidence and the degree of recommendation regarding causes, clinical presentation as well as surgical and medical treatment.
Collapse
Affiliation(s)
- Luiz Griz
- Department of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, University of Pernambuco, Recife, PE, Brazil
| | - Daniele Fontan
- Department of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, University of Pernambuco, Recife, PE, Brazil
| | - Patricia Mesquita
- Department of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, University of Pernambuco, Recife, PE, Brazil
| | - Marise Lazaretti-Castro
- Division of Endocrinology, Department of Medicine, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
| | | | | | - Thyciara Fontenele
- Department of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, University of Pernambuco, Recife, PE, Brazil
| | - Juliana Maia
- Department of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, University of Pernambuco, Recife, PE, Brazil
| | - Francisco Bandeira
- Department of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, University of Pernambuco, Recife, PE, Brazil
| | | |
Collapse
|
5
|
Heymann PG, Mandic R, Kämmerer PW, Kretschmer F, Saydali A, Neff A, Draenert FG. Laser-enhanced cytotoxicity of zoledronic acid and cisplatin on primary human fibroblasts and head and neck squamous cell carcinoma cell line UM-SCC-3. J Craniomaxillofac Surg 2014; 42:1469-74. [DOI: 10.1016/j.jcms.2014.04.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2013] [Revised: 02/23/2014] [Accepted: 04/22/2014] [Indexed: 12/13/2022] Open
|
6
|
Sabatino R, Antonelli A, Battistelli S, Schwendener R, Magnani M, Rossi L. Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells. PLoS One 2014; 9:e101260. [PMID: 24968029 PMCID: PMC4072741 DOI: 10.1371/journal.pone.0101260] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2014] [Accepted: 06/04/2014] [Indexed: 02/08/2023] Open
Abstract
Bisphosphonates, besides being important drugs for the treatment of various bone diseases, could also be used to induce apoptosis in macrophage-like and cancer cells. However, their activity in vivo is limited by a short plasma half-life and rapid uptake within bone. Therefore, several delivery systems have been proposed to modify their pharmacokinetic profile and biodistribution. Among these, red blood cells (RBCs) represent one of the most promising biological carriers. The aim of this study was to select the best performing compound among Clodronate, Pamidronate, Ibandronate and Zoledronate in killing macrophages and to investigate RBCs as innovative carrier system to selectively target bisphosphonates to macrophages. To this end, the encapsulation of the selected bisphosphonates in autologous RBCs as well as the effect on macrophages, both in vitro and in vivo were studied. This work shows that, among the tested bisphosphonates, Zoledronate has proven to be the most active molecule. Human and murine RBCs have been successfully loaded with Zoledronate by a procedure of hypotonic dialysis and isotonic resealing, obtaining a dose-dependent drug entrapment with a maximal loading of 7.96±2.03, 6.95±3.9 and 7.0±1.89 µmoles of Zoledronate/ml of packed RBCs for human, Swiss and Balb/C murine RBCs, respectively. Engineered RBCs were able to detach human and murine macrophages in vitro, leading to a detachment of 66±8%, 67±8% and 60.5±3.5% for human, Swiss and Balb/C RBCs, respectively. The in vivo efficacy of loaded RBCs was tested in Balb/C mice administering 59 µg/mouse of RBC-encapsulated Zoledronate. By a single administration, depletion of 29.0±16.38% hepatic macrophages and of 67.84±5.48% spleen macrophages was obtained, confirming the ability of encapsulated Zoledronate to deplete macrophages in vivo. In conclusion, RBCs loaded with Zoledronate should be considered a suitable system for targeted delivery to macrophages, both in vitro and in vivo.
Collapse
Affiliation(s)
- Raffaella Sabatino
- Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Urbino (PU), Italy
| | - Antonella Antonelli
- Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Urbino (PU), Italy
| | - Serafina Battistelli
- Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Urbino (PU), Italy
| | - Reto Schwendener
- Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland
| | - Mauro Magnani
- Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Urbino (PU), Italy
- EryDel SpA, Urbino (PU), Italy
| | - Luigia Rossi
- Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Urbino (PU), Italy
- EryDel SpA, Urbino (PU), Italy
- * E-mail:
| |
Collapse
|
7
|
Das S, Edwards PA, Crockett JC, Rogers MJ. Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells. Biochim Biophys Acta Mol Cell Biol Lipids 2014; 1841:569-73. [DOI: 10.1016/j.bbalip.2013.12.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Revised: 12/12/2013] [Accepted: 12/17/2013] [Indexed: 11/29/2022]
|